Immune Checkpoint Inhibitors Market by Type (CTLA-4 Inhibitor, PD-1 Inhibitor, and PD-L1 Inhibitor) and Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025 Update Available On-Demand
|
LI_183723
|
Pages: 150
|
Sep
2018 |
4955 Views
|
|
|
|
Author(s) :
Pallavi Jaiswal & Sayali Shinde
|
Tables: 53
|
Charts: 44
|
Formats*:
|
|
Immune Checkpoint Inhibitors Market
The global immune checkpoint inhibitors market was valued at $10,566 million in 2017, and is projected to reach $56,530 million by 2025, registering a CAGR of 20.1% from 2018 to 2025.
Immune checkpoint inhibitor is a type of drug used in immunotherapy. Although traditional chemotherapeutic drugs remain the first-line option for treatment of most cancer types, targeted immune therapies are emerging as standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the recognition and destruction of cancer cells by the immune system.
Surge in prevalence of cancer across geographies and increase in awareness of immune checkpoint inhibitors drive the growth of the global immune checkpoint inhibitors market. Furthermore, technological advancements in screening procedure for cancer, increased healthcare expenditures, increase in government initiatives to alleviate cancer, and rise in public awareness are expected to boost the growth of the market. However, high cost associated with research activities is projected to restrain the market growth.
Get more information on this report : Request Sample Pages
Immune Checkpoint Inhibitors Market Segmentation
The global immune checkpoint inhibitors market is segmented based on type, application, and region. Based on type, the market is classified into CTLA-4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and others. Based on application, it is categorized as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. Based on region, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil and rest of LAMEA).
Segment Review
Based on type, the PD-1 inhibitor segment was the major revenue contributor in 2017, and is anticipated to remain dominant during the forecast period due to increase in adoption of pembrolizumab and nivolumab, globally. However, the demand for PD-L1 inhibitor is projected to exhibit the fastest market growth during the forecast period owing to growth in adoption of durvalumab & avelumab and surge in R&D studies.
Get more information on this report : Request Sample Pages
Based on application, the lung cancer segment presently dominates the market, and is expected to remain dominant during the forecast period, due to rise in prevalence of lung cancer across the globe. Also, increase in use of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC) fuels the growth of this segment. In addition, increase in geriatric population, upsurge in cigarette smoking population, and advancements in diagnostic techniques for lung cancer boost the market growth. Immune checkpoint inhibitors such as pembrolizumab, nivolumab, atezolizumab, and durvalumab are approved for the treatment of NSCLC. Pembrolizumab, developed by Merck & Company, Inc., and nivolumab, developed by Bristol-Myers Squibb are major revenue contributors for bladder cancer segment. However, recently approved drugs atezolizumab, avelumab, and durvalumab are expected to drive the growth of the global immune checkpoint inhibitors market significantly during the forecast period.
Get more information on this report : Request Sample Pages
Snapshot of Asia-pacific Immune Checkpoint Inhibitors Market
Asia-Pacific presents lucrative opportunities for the key players operating in the immune checkpoint inhibitors market, owing to large population base, growth in awareness about advanced immune therapy, surge in incidence of cancer, and improvement of healthcare infrastructure. China, Japan, and India have high prevalence of cancer, which is expected to drive the demand for immune check point inhibitors in near future. However, healthcare insurance providers do not cover the entire expenses for the treatment of cancer. This factor is estimated to hamper the market growth in the Asia-Pacific region.
Get more information on this report : Request Sample Pages
The key players profiled in this report include AstraZeneca PLC., Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.
Key Benefits for Stakeholders
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Immune Checkpoint Inhibitors Market Key Segments:
By Type
- CTLA-4 Inhibitor
- PD-1 Inhibitor
- PD-L1 Inhibitor
- Others
By Application
- Lung Cancer
- Bladder Cancer
- Melanoma
- Hodgkin Lymphoma
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market share analysis
3.3. MARKET DYNAMICS
3.3.1. Drivers
3.3.1.1. Increase in incidence of cancer across the globe
3.3.1.2. Surge in global geriatric population
3.3.1.3. Supportive reimbursement policies for immune checkpoint inhibitors
3.3.1.4. Surge in healthcare expenditure worldwide
3.3.2. Restraint
3.3.2.1. Higher cost of immune checkpoint inhibitors
3.3.3. Opportunities
3.3.3.1. Increase in number of pipeline drugs
3.3.3.2. Growth opportunities in the emerging markets
3.3.4. Impact analyses
3.4. Clinical trials
3.5. Pipeline analyses
CHAPTER 4: IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CTLA-4 inhibitor
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.3. PD-1 inhibitor
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.4. PD-L1 inhibitor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
CHAPTER 5: IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lung cancer
5.2.1. Market size and forecast
5.3. Bladder cancer
5.3.1. Market size and forecast
5.4. Melanoma
5.4.1. Market size and forecast
5.5. Hodgkin lymphoma
5.5.1. Market size and forecast
5.6. Other applications
5.6.1. Market size and forecast
CHAPTER 6: IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.2. Canada
6.2.2.3. Mexico
6.2.3. North America market size and forecast, by type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe market size and forecast, by country
6.3.2.1. Germany
6.3.2.2. France
6.3.2.3. UK
6.3.2.4. Rest of Europe
6.3.3. Europe market size and forecast, by type
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Australia
6.4.2.4. India
6.4.2.5. Rest of Asia-Pacific
6.4.3. Asia-Pacific market size and forecast, by type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Brazil
6.5.2.2. Rest of LAMEA
6.5.3. LAMEA market size and forecast, by type
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product Portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Bristol-Myers Squibb Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Eli Lilly and Company (ARMO BioSciences)
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product Portfolio
7.3.5. Business performance
7.4. Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. Immutep Limited
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product Portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Merck KGaA (EMD Serono, Inc.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product Portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. CLINICAL TRIALS IN IMMUNE CHECKPOINT INHIBITORS MARKET, 2015-2018
TABLE 02. PRODUCT PIPELINE ANALYSIS (PHASE II & III)
TABLE 03. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 04. CTLA-4 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 05. PD-1 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 06. PD-L1 INHIBITOR MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 07. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 08. LUNG CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 09. BLADDER CANCER IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 10. MELANOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 11. HODGKIN LYMPHOMA IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION, 2017-2025 ($MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS MARKET FOR OTHER APPLICATIONS, BY REGION, 2017-2025 ($MILLION)
TABLE 13. IMMUNE CHECKPOINT INHIBITORS MARKET REVENUE, BY REGION, 2017-2025 ($MILLION)
TABLE 14. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 15. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 16. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 17. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 18. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 19. EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 20. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 21. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 22. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 23. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
TABLE 24. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE, 2017-2025 ($MILLION)
TABLE 25. LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
TABLE 26. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 27. ASTRAZENECA: OPERATING SEGMENTS
TABLE 28. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 29. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 30. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 31. LILLY: COMPANY SNAPSHOT
TABLE 32. LILLY: OPERATING SEGMENTS
TABLE 33. LILLY: PRODUCT PORTFOLIO
TABLE 34. FORTRESS: COMPANY SNAPSHOT
TABLE 35. FORTRESS: OPERATING SEGMENTS
TABLE 36. FORTRESS: PRODUCT PORTFOLIO
TABLE 37. ROCHE: COMPANY SNAPSHOT
TABLE 38. ROCHE: OPERATING SEGMENTS
TABLE 39. ROCHE: PRODUCT PORTFOLIO
TABLE 40. IMMUTEP: COMPANY SNAPSHOT
TABLE 41. IMMUTEP: PRODUCT PORTFOLIO
TABLE 42. MERCK: COMPANY SNAPSHOT
TABLE 43. MERCK: OPERATING SEGMENTS
TABLE 44. MERCK: PRODUCT PORTFOLIO
TABLE 45. MERCK: COMPANY SNAPSHOT
TABLE 46. MERCK: OPERATING SEGMENTS
TABLE 47. MERCK: PRODUCT PORTFOLIO
TABLE 48. NOVARTIS: COMPANY SNAPSHOT
TABLE 49. NOVARTIS: OPERATING SEGMENTS
TABLE 50. NOVARTIS: PRODUCT PORTFOLIO
TABLE 51. PFIZER: COMPANY SNAPSHOT
TABLE 52. PFIZER: OPERATING SEGMENTS
TABLE 53. PFIZER: PRODUCT PORTFOLIO LIST OF FIGURES
LIST OF FIGURES
FIGURE 01. IMMUNE CHECKPOINT INHIBITORS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MARKET SHARE ANALYSIS, 2017
FIGURE 04. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 05. IMPACT ANALYSES
FIGURE 06. U.S. IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 07. CANADA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 08. MEXICO IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 09. GERMANY IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 10. FRANCE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 11. UK IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 12. REST OF EUROPE IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 13. JAPAN IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 15. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 16. INDIA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 17. REST OF ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 18. BRAZIL IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 19. REST OF LAMEA IMMUNE CHECKPOINT INHIBITORS MARKET, 2017-2025 ($MILLION)
FIGURE 20. ASTRAZENECA: REVENUE, 2015-2017 ($MILLION)
FIGURE 21. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 22. REVENUE, 2015-2017 ($MILLION)
FIGURE 23. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 24. REVENUE, 2015-2017 ($MILLION)
FIGURE 25. LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 26. LILLY: REVENUE SHARE BY REGION, 2017 (%)
FIGURE 27. FORTRESS: NET SALES, 2015-2017 ($MILLION)
FIGURE 28. FORTRESS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 29. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 30. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 31. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. IMMUTEP: NET SALES, 2015-2017 ($MILLION)
FIGURE 33. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 34. MERCK: NET SALES BY SEGMENT, 2017 (%)
FIGURE 35. MERCK: NET SALES BY GEOGRAPHY, 2017 (%)
FIGURE 36. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. NET SALES, 2015-2017 ($MILLION)
FIGURE 40. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. PFIZER: REVENUE, 2015-2017 ($MILLION)
FIGURE 43. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Immune checkpoint inhibitors are a new form of immune therapy, which is used in the treatment of cancer. The adoption of immune checkpoint inhibitors is expected to increase in the near future, majorly due to rise in prevalence of cancer across the globe. Moreover, surge in demand for advanced therapeutics for the treatment of cancer, due to high unmet medical needs propels the growth of the market.
Rise in diagnosis of cancer in the developing countries, surge in R&D for combination studies of checkpoint inhibitors, and increase in awareness about immune checkpoint inhibitors in the developing countries are projected to supplement the market growth during the forecast period. However, complications and higher cost associated with the use of immune checkpoint inhibitors are expected to hinder the market growth.
North America is expected to remain dominant during the forecast period, due to surge in use of immune checkpoint inhibitors, owing to presence of advanced healthcare facilities and higher number of target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to developments in healthcare infrastructure coupled with rise in demand for immune checkpoint inhibitors.
Download Sample
Purchase Full Report of
Immune Checkpoint Inhibitors Market- Global Opportunity Analysis and Industry Forecast, 2018-2025
- Online Only
- $3,456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,840
- Restricted to one authorized user
- One print only
- Available in Excel
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5,370
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,995
- Unlimited within company/enterprise
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"Immune Checkpoint Inhibitors Market"
Purchase Enquiry